A disorder of cortical GABAergic innervation in Alzheimer's disease

Neurosci Lett. 1987 Jan 14;73(2):192-6. doi: 10.1016/0304-3940(87)90016-4.

Abstract

Synaptosomal gamma-aminobutyric acid (GABA) uptake has been used as a biochemical marker for GABAergic terminals in controls and Alzheimer disease brains. Use of this marker suggests a large (ca. 70%) loss of cortical and hippocampal GABA terminals in Alzheimer brain. To explain this observation we suggest that neuron loss in this disorder occurs via a process of cortical retrograde degeneration. This scheme reconciles our findings with previous neurochemical measurements on Alzheimer disease brains and also better reconciles the biochemistry with the histology of the disorder.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / pathology
  • Alzheimer Disease / physiopathology*
  • Cerebral Cortex / pathology
  • Cerebral Cortex / physiopathology*
  • Female
  • Hippocampus / pathology
  • Hippocampus / physiopathology*
  • Humans
  • Male
  • Middle Aged
  • Synaptosomes / metabolism
  • gamma-Aminobutyric Acid / physiology*

Substances

  • gamma-Aminobutyric Acid